307 related articles for article (PubMed ID: 26981724)
1. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of small molecule hedgehog inhibitor and miRNA for treating pancreatic cancer.
Kumar V; Mondal G; Slavik P; Rachagani S; Batra SK; Mahato RI
Mol Pharm; 2015 Apr; 12(4):1289-98. PubMed ID: 25679326
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
4. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
5. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
6. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.
Kumar V; Mundra V; Peng Y; Wang Y; Tan C; Mahato RI
Theranostics; 2018; 8(15):4033-4049. PubMed ID: 30128034
[No Abstract] [Full Text] [Related]
8. Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis.
Almawash SA; Mondal G; Mahato RI
Pharm Res; 2018 Jan; 35(1):17. PubMed ID: 29305793
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of Self-Assembling Polymer-Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice.
Kattel K; Mondal G; Lin F; Kumar V; Mahato RI
Mol Pharm; 2017 May; 14(5):1365-1372. PubMed ID: 27798825
[TBL] [Abstract][Full Text] [Related]
10. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Kim EJ; Sahai V; Abel EV; Griffith KA; Greenson JK; Takebe N; Khan GN; Blau JL; Craig R; Balis UG; Zalupski MM; Simeone DM
Clin Cancer Res; 2014 Dec; 20(23):5937-5945. PubMed ID: 25278454
[TBL] [Abstract][Full Text] [Related]
11. Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Chitkara D; Mittal A; Behrman SW; Kumar N; Mahato RI
Bioconjug Chem; 2013 Jul; 24(7):1161-73. PubMed ID: 23758084
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
13. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
14. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
15. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis.
Kumar V; Dong Y; Kumar V; Almawash S; Mahato RI
Theranostics; 2019; 9(25):7537-7555. PubMed ID: 31695785
[No Abstract] [Full Text] [Related]
16. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
17. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
Liang TJ; Zhou ZM; Cao YQ; Ma MZ; Wang XJ; Jing K
Int J Pharm; 2016 Nov; 513(1-2):564-571. PubMed ID: 27613255
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Mittal A; Chitkara D; Behrman SW; Mahato RI
Biomaterials; 2014 Aug; 35(25):7077-87. PubMed ID: 24836307
[TBL] [Abstract][Full Text] [Related]
20. Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Awasthi N; Schwarz MA; Schwarz RE
HPB (Oxford); 2011 Sep; 13(9):597-604. PubMed ID: 21843259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]